JP2019516675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516675A5 JP2019516675A5 JP2018555634A JP2018555634A JP2019516675A5 JP 2019516675 A5 JP2019516675 A5 JP 2019516675A5 JP 2018555634 A JP2018555634 A JP 2018555634A JP 2018555634 A JP2018555634 A JP 2018555634A JP 2019516675 A5 JP2019516675 A5 JP 2019516675A5
- Authority
- JP
- Japan
- Prior art keywords
- peg
- pharmaceutically acceptable
- acceptable salt
- ala
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710142969 Somatoliberin Proteins 0.000 claims description 21
- 229920000642 polymer Polymers 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 12
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 6
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 4
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims description 4
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- UHEGDWIZAOPGIY-UHFFFAOYSA-N 3-[3-(5-benzyl-2-carbamoylphenyl)phenyl]propanoic acid Chemical compound C(C1=CC=CC=C1)C=1C=CC(=C(C=1)C1=CC(=CC=C1)CCC(=O)O)C(N)=O UHEGDWIZAOPGIY-UHFFFAOYSA-N 0.000 claims description 3
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 3
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960003104 ornithine Drugs 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102100022831 Somatoliberin Human genes 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 102000018997 Growth Hormone Human genes 0.000 claims 2
- 108010051696 Growth Hormone Proteins 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 241000406668 Loxodonta cyclotis Species 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 241000024188 Andala Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324600P | 2016-04-19 | 2016-04-19 | |
| US62/324,600 | 2016-04-19 | ||
| PCT/CA2017/050475 WO2017181277A1 (en) | 2016-04-19 | 2017-04-18 | Pegylated bioactive peptides and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516675A JP2019516675A (ja) | 2019-06-20 |
| JP2019516675A5 true JP2019516675A5 (enExample) | 2021-11-11 |
| JP7134093B2 JP7134093B2 (ja) | 2022-09-09 |
Family
ID=60039750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555634A Active JP7134093B2 (ja) | 2016-04-19 | 2017-04-18 | ペグ化バイオアクティブペプチド及びその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9988428B2 (enExample) |
| EP (1) | EP3445778B1 (enExample) |
| JP (1) | JP7134093B2 (enExample) |
| KR (1) | KR102520348B1 (enExample) |
| CN (1) | CN109153712B (enExample) |
| AU (1) | AU2017254754B2 (enExample) |
| BR (1) | BR112018070929A2 (enExample) |
| CA (1) | CA3021231A1 (enExample) |
| DK (1) | DK3445778T3 (enExample) |
| ES (1) | ES2824781T3 (enExample) |
| HU (1) | HUE052802T2 (enExample) |
| IL (1) | IL262356B2 (enExample) |
| MX (1) | MX2018012716A (enExample) |
| PL (1) | PL3445778T3 (enExample) |
| PT (1) | PT3445778T (enExample) |
| RU (1) | RU2748576C2 (enExample) |
| SG (1) | SG11201808880PA (enExample) |
| WO (1) | WO2017181277A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202110469PA (en) | 2019-03-29 | 2021-10-28 | Massachusetts Gen Hospital | Ghrh or analogues thereof for use in treatment of hepatic disease |
| CN116194344A (zh) | 2020-10-09 | 2023-05-30 | 奥托立夫开发公司 | 安全气囊装置 |
| CN114195881B (zh) * | 2021-12-16 | 2022-09-16 | 浙江湃肽生物股份有限公司 | 一种制备醋酸舍莫瑞林的方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4659693A (en) | 1984-04-30 | 1987-04-21 | Syntex (U.S.A.) Inc. | N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides |
| US4622312A (en) | 1984-09-24 | 1986-11-11 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
| US4689318A (en) | 1985-08-29 | 1987-08-25 | The Salk Institute For Biological Studies | GRF analogs |
| US4914189A (en) | 1987-02-05 | 1990-04-03 | The Adminstrators Of The Tulane Educational Fund | Synthetic GHRH analogs |
| DE3726324A1 (de) | 1987-08-07 | 1989-02-16 | Hoechst Ag | Cyclopeptide als resorptionsfoerderer bei applikation auf die schleimhaeute |
| US5023322A (en) | 1988-08-31 | 1991-06-11 | Mta Kutatas-Es Szervezetelemzo Intezete | Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof |
| US5084442A (en) | 1988-09-06 | 1992-01-28 | Hoffmann-La Roche Inc. | Cyclic growth hormone releasing factor analogs and method for the manufacture thereof |
| US5137872A (en) | 1989-09-18 | 1992-08-11 | Pitman-Moore, Inc. | Growth hormone-releasing factor analogs |
| NZ238748A (en) | 1990-06-29 | 1993-09-27 | Hoffmann La Roche | Growth hormone releasing factor (grf) analogues |
| US5847006A (en) | 1991-02-08 | 1998-12-08 | Cambridge Neuroscience, Inc. | Therapeutic guanidines |
| EP0542937A1 (en) | 1991-04-09 | 1993-05-26 | F. Hoffmann-La Roche Ag | Growth hormone releasing factor analogs |
| CA2158782C (en) | 1994-09-23 | 2010-01-12 | Pierrette Gaudreau | Marker for growth hormone-releasing factor receptors |
| US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| JPH11503454A (ja) | 1995-04-14 | 1999-03-26 | ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド | 成長ホルモン放出因子の類似体 |
| ES2163020T3 (es) | 1995-05-26 | 2002-01-16 | Theratechnologies Inc | Analogos quimericos de factor liberador de hormona de crecimiento (grf) de cuerpo graso, provistos de mayor potencia biologica. |
| EP0922446A1 (en) * | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
| US6696063B1 (en) | 1998-12-30 | 2004-02-24 | Applied Research Systems Ars Holding N.V. | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
| ATE309358T1 (de) | 1999-07-26 | 2005-11-15 | Baylor College Medicine | Superaktive, wachstumshormone freisetzende hormonanaloge vom schwein |
| AU9558901A (en) | 2000-10-05 | 2002-04-15 | Ares Trading Sa | Regioselective liquid phase pegylation |
| MXPA05002991A (es) | 2002-09-18 | 2005-10-05 | Univ Montreal Ct Hospitalier Chum | Analogos de ghrh. |
| US20050059605A1 (en) | 2003-01-31 | 2005-03-17 | Krishna Peri | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| AU2003229222B2 (en) | 2003-05-29 | 2009-11-12 | Theratechnologies Inc. | GRF analog compositions and their use |
| WO2007025988A2 (en) * | 2005-08-30 | 2007-03-08 | Novo Nordisk Health Care Ag | Liquid formulations of pegylated growth hormone |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| US20110021429A1 (en) | 2007-10-01 | 2011-01-27 | Pierrette Gaudreau | Renoprotection by growth hormone-releasing hormone and agonists |
| JP2011511778A (ja) * | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| US8796216B2 (en) | 2008-06-12 | 2014-08-05 | Syntaxin Limited | Suppression of neuroendocrine diseases |
| ES2732205T3 (es) | 2008-06-12 | 2019-11-21 | Ipsen Bioinnovation Ltd | Proteínas de fusión para uso en el tratamiento del cáncer |
| CA2745499A1 (en) | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Peptide therapeutic conjugates and uses thereof |
| MX2013012259A (es) * | 2011-04-21 | 2013-11-22 | Theratechnologies Inc | Analogos del factor de liberacion de la hormona de crecimiento (grf) y usos de estos. |
| BR112014009418A2 (pt) | 2011-10-18 | 2017-04-18 | Aileron Therapeutics Inc | macrociclos peptidomiméticos |
| US9079974B2 (en) | 2011-12-21 | 2015-07-14 | The University Of Miami | GH-RH analogs with potent agonistic effects |
| CN104946659A (zh) * | 2015-03-27 | 2015-09-30 | 杭州北斗生物技术有限公司 | 重组人生长激素的制备方法及其peg化修饰物的制备方法 |
| WO2017023933A2 (en) * | 2015-08-03 | 2017-02-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
-
2017
- 2017-04-18 SG SG11201808880PA patent/SG11201808880PA/en unknown
- 2017-04-18 PT PT177851995T patent/PT3445778T/pt unknown
- 2017-04-18 JP JP2018555634A patent/JP7134093B2/ja active Active
- 2017-04-18 CA CA3021231A patent/CA3021231A1/en active Pending
- 2017-04-18 WO PCT/CA2017/050475 patent/WO2017181277A1/en not_active Ceased
- 2017-04-18 KR KR1020187033365A patent/KR102520348B1/ko active Active
- 2017-04-18 US US15/490,618 patent/US9988428B2/en active Active
- 2017-04-18 HU HUE17785199A patent/HUE052802T2/hu unknown
- 2017-04-18 PL PL17785199.5T patent/PL3445778T3/pl unknown
- 2017-04-18 EP EP17785199.5A patent/EP3445778B1/en active Active
- 2017-04-18 ES ES17785199T patent/ES2824781T3/es active Active
- 2017-04-18 US US16/094,565 patent/US10918730B2/en active Active
- 2017-04-18 DK DK17785199.5T patent/DK3445778T3/da active
- 2017-04-18 AU AU2017254754A patent/AU2017254754B2/en not_active Ceased
- 2017-04-18 MX MX2018012716A patent/MX2018012716A/es unknown
- 2017-04-18 CN CN201780021914.8A patent/CN109153712B/zh not_active Expired - Fee Related
- 2017-04-18 RU RU2018140501A patent/RU2748576C2/ru active
- 2017-04-18 BR BR112018070929-8A patent/BR112018070929A2/pt not_active IP Right Cessation
-
2018
- 2018-10-14 IL IL262356A patent/IL262356B2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013515055A5 (enExample) | ||
| EP2326341B1 (en) | Oxytocin formulations and uses thereof | |
| JP2014530868A5 (enExample) | ||
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| JP2011526886A5 (enExample) | ||
| JP2013518090A5 (enExample) | ||
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| JP2013517307A5 (enExample) | ||
| US20150299286A1 (en) | Glutamic acid-stabilized insulin analogues | |
| JP2019516675A5 (enExample) | ||
| RU2010144014A (ru) | Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств | |
| JP2019533722A5 (enExample) | ||
| JP2020040988A (ja) | 長時間作用型アドレノメデュリン誘導体 | |
| RU2012136530A (ru) | Новые соединения, влияющие на пищевое поведение | |
| RU2016110153A (ru) | Новые пептиды и их аналоги для применения при лечении мукозита полости рта | |
| RU2018140501A (ru) | Пэгилированные биологически активные пептиды и их применение | |
| JP2017502003A5 (enExample) | ||
| JP2012516693A5 (enExample) | ||
| JP2010506844A5 (enExample) | ||
| EP3701966A1 (en) | Drug and method for treating liver diseases related to hepatitis b viruses in full-dose condition | |
| JP2020515283A5 (enExample) | ||
| JP2014515751A5 (enExample) | ||
| HU199301B (en) | Process for producing pharmaceutical compositions comprising cyclopeptide as auxiliary | |
| WO2017149098A1 (en) | Fusion respiratory syncytial virus inhibitors and use thereof | |
| JPWO2009107766A1 (ja) | 経鼻投与用医薬組成物 |